Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-22

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open label, randomized controlled clinical trial study will be conducted after obtaining ERC approval of Bahria University Health Sciences. Written informed consent will be taken from all study participants. Patients suffering from moderate to severe chronic periodontitis and diagnosed as per criteria Community Periodontal Index for Treatment Needs (CPITN) (Heiko Z et al, 2015) will be selected from the Oral Diagnostic \& Periodontology department of Islamabad Medical \& Dental College hospital . Patients will be randomized into 3 groups by using computer driven list. Sample size will be calculated by using software G power version3.1.9.2 . Patients will be randomly divided into 3 groups.

(I) Baseline investigations/parameters (at day zero): FBS values will be monitored using digital glucometer Clinical parameters (PI, CAL, PDD, mSBI) will be assessed at baseline, 3 , 6 , 9 \& 12 months by calibrated periodontal probe. Radiological parameters (VBL \& IBDA) will be carried out using OPG at baseline, 6 \& 12 months. ELISA for Transforming growth factor (TGFβ) and osteocalcin biomarkers will be done at baseline and 3 months. RT-PCR for the detection of RUNX2 gene will be done at baseline and 3 months Patient will be called at 14th day for suture removal and clinical assessment . Follow up will be done at 3, 6, 9 and 12 months to assess clinically. Radiographic parameters will be assessed at 6 \&12 months. Pharmacogenetic parameters will be assessed at 6months. All patients will be advised regular check-ups post surgically at per appointment . Individual study period will be 12 months. Total duration of study will be 15 months.

Primary outcomes:

Reduction in intra-bony defect angle and vertical bone loss. Periodontal and alveolar bone regeneration by detecting the levels of biomarkers namely, transforming growth factor β, osteocalcin

Secondary Outcomes:

Osteogenic proliferation : Evaluation of RUNX2 expression in response to Metformin \& Alendronate 1% gel administration will be assessed per subject per genetic analysis.

RUNX2 expression will be observed through RT- PCR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Alendronate Compared to Metformin in Chronic Periodontitis

NCT02461667

Chronic Periodontitis

COMPLETED PHASE2/PHASE3

Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy

NCT03343366

Chronic Periodontitis Type 2 Diabetes Mellitus

COMPLETED PHASE2/PHASE3

Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis

NCT03204071

Chronic Periodontitis

COMPLETED PHASE2/PHASE3

1% Metformin in Moderate and Severe Periodontitis

NCT02274090

Periodontitis

COMPLETED PHASE2/PHASE3

Effectiveness of Periodontal Treatment for the Glycemic Conttrol of Type II Diabetes Mellitus

NCT05587413

Patient Compliance

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This open -label randomized controlled clinical trial study will be conducted after obtaining IRB approval of Bahria University Health Sciences Campus, Karachi. Written informed consent will be taken from all study participants. Patients suffering from moderate to severe chronic periodontitis and diagnosed as per criteria Community Periodontal Index for Treatment Needs (CPITN) will be selected from the Oral Diagnostic \& Periodontology department of Islamabad Medical \& Dental College. Patients will be randomized into 3 groups by using computer driven list.

A. Group A: PRF alone (Control group, n=40) B. Group B: 1% Metformin gel + PRF (test group,n=40) C. Group C : 1% Alendronate gel + PRF (test group,n=40) Clinical examination will be done at baseline, 3,6,9 \& 12 months by means of periodontal probe assessing PDD, CAL, mSBI, PI for the diagnosis of chronic periodontitis. Radiological parameters ( VBL, IBDDR \& IBDA) will be carried out using orthopantamogram at baseline and 6 months. Patients will be advised not to eat 2 hours prior treatment . Paper points #30 (GAPADENT) sterilized colour coded will be used for the collection of gingival crevicular fluid from the crevicular site. Selected affected tooth with deep periodontal pocket and clinical attachment loss will be isolated with cotton rolls to prevent salivary contamination, supra-gingival plaque will be removed without disturbing the soft tissues, and the tooth will be dried with a gentle stream of air for 5s. Gingival crevicular fluid will preferably be collected by absorption technique from the affected tooth. Absorbent paper points #30 will be standardized to three in quantity for Gingival crevicular fluid sampling. These will be placed into the periodontal pocket of the affected tooth with the greatest pocket depth (≥4mm) in each patient till mild resistance is felt. The paper points were left for 30 seconds to collect the resting GCF. The paper points contaminated with blood or saliva will be discarded .The sample will be transferred to Eppendorf tubes (2 ml) containing 150 µl phosphate-buffered saline (PBS; Sigma Aldrich, St. Louis, M) , centrifuged at 10,000 Rev/min for 5 mins and stored at -800C 14. Genotyping- DNA sequence variation for RUNX2 will be done by real time PCR.14, 25. Transforming growth factor-β (TGF-β) and osteocalcin will be assessed by ELISA. Intra- sulcular incision with mucoperiosteal flap elevation, debridement of granulation tissue, subgingival SRP, and rinsing with normal saline solution will be performed. For the prepaartion of PRF Intravenous blood from the antecubital vein will be collected in three, 10-ml sterilized test tubes. No anticoagulant will be added to the tubes and instantly centrifuged in centrifugation machine at 3000 RPM for 10 min. The formation of structured fibrin clot in the centre of the tube, just in the middle of the red corpuscles at the base and acellular plasma (platelet-poor plasma \[PPP\]) at the top. PRF will be separated from RBCs using sterile tweezers and scissors just after the removal of PPP. Then, it will be transferred onto sterile gauze , compress so as to squeeze out the serum out of a stable PRF membrane. This membrane will be placed at the site along with gel administration by means of syringe. Group A (control) will undergo open flap debridement (OFD) with platelet rich fibrin (PRF) only, Group B will have OFD with administration of 1% Metformin gel in adjunct to PRF and Group C will have OFD with administration of 1% Alendronate gel in adjunct to PRF. Patient will be called for suture removal at day 14. Follow up will be done at 3, 6, 9 \& 12 months to assess clinical parameters . Biochemical and pharmacogenetic parameters will be assessed 3 months . Radiographic parameters will be assessed at 6 \& 9 months. All patients will be advised regular check-ups post surgically . Data analysis will be performed by statistical software package SPSS version 23. The frequencies and percentages will be calculated for categorical data while mean with standard deviation will be calculated for continuous characteristics. Intra-group comparison will be analysed by paired Student's t-test. Inter-group comparison analysis will be done by ANOVA. Multiple comparison analysis will be performed by Post Hoc. P-value \< 0.05 is considered significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alveolar Bone Loss Associated Chronic Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Platelet Rich Fibrin

Group A - administration of Platelet rich fibrin only, subgingivally , once in 6 months

Group Type ACTIVE_COMPARATOR

Platelet rich fibrin

Intervention Type PROCEDURE

sub-gingival administration of platelet rich fibrin following open flap surgery

Metformin

Group -B - Platelet Rich Fibrin +1% Metformin gel, once sub-gingivally in 6 months

Group Type ACTIVE_COMPARATOR

Metformin hydrochloride powder

Intervention Type DRUG

subgingival administration of 1% Metformin Hydrochloride gel with platelet rich fibrin following open flap surgery

Alendronate

Group C- Platelet rich fibrin + 1% Alendronate gel , once sub-gingivally in 6 months

Group Type ACTIVE_COMPARATOR

alendronate sodium powder

Intervention Type DRUG

subgingival administration of 1% Alendronate gel with platelet rich fibrin following open flap surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Platelet rich fibrin

sub-gingival administration of platelet rich fibrin following open flap surgery

Intervention Type PROCEDURE

Metformin hydrochloride powder

subgingival administration of 1% Metformin Hydrochloride gel with platelet rich fibrin following open flap surgery

Intervention Type DRUG

alendronate sodium powder

subgingival administration of 1% Alendronate gel with platelet rich fibrin following open flap surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Males and females

* Age 25-50 years
* Systemically healthy individuals
* Probing depth sites ≥ 5mm- \<7 mm pocket depth (PD)\[American Dental Association/ Academy of Periodontology 1999) Clinical attachment level (CAL) ≥4mm- \<5 mm \[ American Dental Association/ Academy of Periodontology 1999)
* Vertical bone loss (VBL) ≥3mm on intraoral periapical radiographs.\[American Academy of Periodontology Guidelines, 1999\]
* Modified Sulcus bleeding index (mSBI) \[Muhlemann and Sons index,1971; Augusta B Rebelo et al,2011\]
* No history of periodontal treatment in the previous 6 months

Exclusion Criteria

* • Individuals \<20 and \>50 yrs

* Patients with known systemic disease such as diabetes, hypertension, osteoporosis etc.
* Patients with severe periodontitis
* Pregnant and lactating mothers
* Patients receiving medications

Minimum Eligible Age

30 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes